The Genomics Resource Center (GRC) at the Institute for Genome Sciences (IGS) has a scientific pedigree and a sample-to-interpretation service commitment that place it in a league of its own. The team operates under a simple mantra: ‘If it can be sequenced, we can do it.’
Both GRC and IGS were founded in 2007 when a high-powered team of investigators formerly at The Institute for Genomic Research (TIGR), led by Claire Fraser, joined the University of Maryland School of Medicine. “The group of faculty and senior staff that came here to start the institute was heavily focused on infectious disease research,” says Luke Tallon, scientific director and founding leader of the GRC. “Our primary goal in joining the medical school was to extend our pathogen genomics expertise into host-pathogen studies and direct clinical genomics applications.”
In addition to its infectious disease and genomics expertise, TIGR was also renowned for its bioinformatics talent — a trait that continues with the group at IGS. The GRC team of 15 staff members is evenly split between wet lab and bioinformatics, and more than half of the institute’s 100-plus employees are bioinformaticians. “One of our strengths is that we go beyond generating efficient, high-quality sequence data. We have teams of analysts and engineers who can assist investigators with downstream analysis and interpretation,” Tallon says.
The GRC has had a mandate to stay on the cutting edge of sequencing technology since its inception. “We are continuously monitoring and evaluating new technologies,” Tallon says. A few years ago, these evaluations led IGS to Pacific Biosciences and its single molecule, real-time (SMRT®) sequencer.
The instrument’s strength in de novo microbial sequencing and other long-read applications made it particularly well-suited to the type of research at IGS. Though there are many factors they consider when choosing a new instrument, an important one is “the relative value of the type of data you’re going to get,” Tallon says. “Small genomes are such a significant part of what we do, and we’re moving more and more into microbial transcriptomes and methylation studies. It’s the only platform that allows us to do all of that really well.”
Lisa Sadzewicz, administrative director of the facility, notes that anticipated demand is also an important factor in bringing in a new instrument for a core facility. “We are not driven by only one customer or one small group,” she says. “In order to drive down costs, you need to have a wide community from which you can draw projects and samples to fill the capacity of the instrument.”
The PacBio sequencer, which GRC upgraded to the PacBio® RS II last spring, is now a workhorse for generating finished or nearly complete microbial genomes as well as genome-wide methylation data. “We’re now analyzing base modifications and methylation patterns routinely with most of our small genomes,” Tallon says. “We’re also doing metagenomic sequencing using the RS II and exploring ways we can use the long reads to get full-length genes and transcripts out of our metagenome and metatranscriptome samples.”
The team’s attention to optimizing the sequencing workflow has resulted in a high-performance pipeline for finishing genomes. “Prior to PacBio, we couldn’t close genomes without manual finishing efforts,” Tallon says. With SMRT Sequencing, his team is consistently finishing genomes. “Our biggest challenge is getting sufficient high-quality DNA to start a project. If we get that, the genomes are going to close more often than not.”
For more on the GRC’s use of the PacBio system, including details on how the lab optimized its SMRT pipeline, read the complete profile. You can also visit the GRC blog or attend their upcoming applications seminar to hear how the PacBio RS II can advance your research on Thursday, November 7 at 11:00 AM. http://blog.pacificbiosciences.com/2013/11/at-institute-for-genome-sciences-long.html?utm_content=bufferb6ae0&utm_source=buffer&utm_medium=twitter&utm_campaign=Buffer ( Pacific Biosciences ?@PacBio 2h Blog Post: At Institute for Genome Sciences, Long Reads Offer New Path to Finished Genomes http://j.mp/187IPyb @
Recent PACB News
- Ambry Genetics and PacBio Announce Collaboration to Sequence Up to 7,000 Human Genomes Aimed at Providing Answers for Families Battling Rare Diseases • PR Newswire (US) • 05/15/2024 01:45:00 PM
- Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers • Edgar (US Regulatory) • 05/09/2024 08:33:12 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/09/2024 08:21:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 08:12:15 PM
- PacBio Announces First Quarter 2024 Financial Results • PR Newswire (US) • 05/09/2024 08:05:00 PM
- PacBio Announces Preliminary First Quarter 2024 Revenue and Updates 2024 Revenue Guidance • PR Newswire (US) • 04/16/2024 12:05:00 PM
- Estonia National Biobank Selects PacBio to Sequence 10,000 Whole Genomes • PR Newswire (US) • 03/27/2024 12:00:00 PM
- PacBio Grants Equity Incentive Award to New Employee • PR Newswire (US) • 03/22/2024 08:30:00 PM
- PacBio Announces PureTarget™ Repeat Expansion Panel, Expanding its Portfolio of End-to-End Clinical Research Solutions • PR Newswire (US) • 03/12/2024 01:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:36:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:30:18 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:26:40 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/06/2024 10:22:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:32:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/04/2024 11:22:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:55:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:36:09 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:25:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/26/2024 09:19:42 PM
- PacBio to Present at Upcoming Investor Conferences • PR Newswire (US) • 02/26/2024 09:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:25:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:17:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/21/2024 11:07:18 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 02/20/2024 09:17:12 PM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM
Greenlite Ventures Inks Deal to Acquire No Limit Technology • GRNL • May 17, 2024 3:00 PM
Music Licensing, Inc. (OTC: SONG) Subsidiary Pro Music Rights Secures Final Judgment of $114,081.30 USD, Demonstrating Strength of Licensing Agreements • SONGD • May 17, 2024 11:00 AM
VPR Brands (VPRB) Reports First Quarter 2024 Financial Results • VPRB • May 17, 2024 8:04 AM
ILUS Provides a First Quarter Filing Update • ILUS • May 16, 2024 11:26 AM